Technical Analysis for EVG - Evgen Pharma Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 18 hours ago |
| Down 1% | about 18 hours ago |
| 10 DMA Support | about 18 hours ago |
| Rose Above 10 DMA | about 18 hours ago |
| Rose Above 10 DMA | 1 day ago |
Get this analysis on your stocks daily!
Evgen Pharma Plc Description
Evgen Pharma plc is a clinical-stage drug development company focused on cancer and neurological disease. The Company operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01: breast cancer; SFX-01: subarachnoid hemorrhage, and other programs. The objective of SFX-01 therapy is to reduce the number of cancer stem cells (CSCs) proliferating in tumors treated with anti-hormonal agents and prolong the duration of response. The objective of SFX-01 therapy (co-administered with standard-of-care nimodipine) is to reduce the vasospasm and incidence of delayed cerebral ischemia in the days following the hemorrhage. It has a preclinical SFX-01 program in multiple sclerosis and a clinical interest in prostate cancer.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Chemistry Pharmaceutical Medicine Cancer Disease Pipe Clinic Therapy Pharmaceutical Products Drug Development Tumor Multiple Sclerosis Scs Prostate Cancer Breast Cancer Stem Cells Intensive Care Medicine Neurosurgery Tumors Asos Organic Chemistry
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.05 |
| 52 Week Low | 0.7 |
| Average Volume | 1,286,421 |
| 200-Day Moving Average | 1.78 |
| 50-Day Moving Average | 0.96 |
| 20-Day Moving Average | 0.82 |
| 10-Day Moving Average | 0.77 |
| Average True Range | 0.06 |
| RSI (14) | 29.08 |
| ADX | 9.87 |
| +DI | 15.09 |
| -DI | 19.20 |
| Chandelier Exit (Long, 3 ATRs) | 0.83 |
| Chandelier Exit (Short, 3 ATRs) | 0.89 |
| Upper Bollinger Bands | 0.95 |
| Lower Bollinger Band | 0.70 |
| Percent B (%b) | 0.31 |
| BandWidth | 30.74 |
| MACD Line | -0.07 |
| MACD Signal Line | -0.07 |
| MACD Histogram | 0.0084 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.80 | ||||
| Resistance 3 (R3) | 0.80 | 0.79 | 0.79 | ||
| Resistance 2 (R2) | 0.79 | 0.78 | 0.79 | 0.79 | |
| Resistance 1 (R1) | 0.78 | 0.78 | 0.78 | 0.78 | 0.79 |
| Pivot Point | 0.77 | 0.77 | 0.77 | 0.77 | 0.77 |
| Support 1 (S1) | 0.77 | 0.76 | 0.77 | 0.77 | 0.76 |
| Support 2 (S2) | 0.76 | 0.76 | 0.76 | 0.76 | |
| Support 3 (S3) | 0.75 | 0.76 | 0.76 | ||
| Support 4 (S4) | 0.75 |
